Xenon Pharmaceuticals (NASDAQ:XENE) PT Raised to $56.00 at B

Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target raised by Bank of America from $52.00 to $56.00 in a research report sent to investors on Tuesday, Benzinga reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on XENE. StockNews.com […]

Related Keywords

China , United States , Canada , America , Gary Patou , Analyst Recommendations For Xenon Pharmaceuticals , Nasdaq , Institutional Trading Of Xenon Pharmaceuticals , Insider Transactions At Xenon Pharmaceuticals , Xenon Pharmaceuticals , Jpmorgan Chase Co , News Ratings For Xenon Pharmaceuticals Daily , Xenon Pharmaceuticals Price Performance , Xenon Pharmaceuticals Inc , China Universal Asset Management Co , Cantor Fitzgerald , Securities Exchange Commission , Wells Fargo Company , Royal Bank , Free Report , Moderate Buy , Get Free Report , Director Gary Patou , Exchange Commission , China Universal Asset Management , Universal Asset Management , Pharmaceuticals Inc , Xenon Pharmaceuticals Daily , Nasdaq Xene , Exene , Medical , Boost Price Target , Bank Of America Co ,